© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
January 30, 2015
TKIs have been an invaluable addition to the treatment of thyroid cancers, including medullary thyroid cancer, but adverse events must be effectively monitored and managed.
Advances in molecular testing have enabled families of those with thyroid cancers to determine whether or not they may be at increased risk for developing thyroid cancer.
January 29, 2015
With appropriate treatment, individuals with thyroid cancer have good odds for survivalâ€”the 5-year survival rate is 98%. Many factors influence the risk of survival after thyroid cancer is diagnosed.
Carrie C. Lubitz, MD, MPH, assistant professor, Massachusetts General Hospital, discusses the diagnosis of thyroid cancer.
January 28, 2015
Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the challenges associated with treating patients with follicular cell-derived thyroid carcinoma.
Each year approximately 63,000 persons in the US will be diagnosed with thyroid cancer, placing it among the top 10 most common cancers in the country.
January 26, 2015
Over the past few decades, the annual incidence of OPSCC has increased sharply in several countries, including in the United States.
Lily Kwatampora, MD, discusses the relationship between body composition and targeted therapies in patients with thyroid cancer.